1260653-09-5 Usage
Description
1-(2,3-Dimethylphenyl)-6,7-dihydro-1H-indazol-4(5H)-one is a heterocyclic compound characterized by a fused indazole and cyclopentanone ring system. It is a derivative of indazole, a nitrogen-containing aromatic heterocycle, and features a 2,3-dimethylphenyl group substitution at the 1-position. This chemical structure endows it with potential pharmaceutical applications and suggests that it may exhibit significant biological activities.
Uses
Used in Pharmaceutical Industry:
1-(2,3-Dimethylphenyl)-6,7-dihydro-1H-indazol-4(5H)-one is used as a potential drug candidate for its possible biological activities. 1-(2,3-Dimethylphenyl)-6,7-dihydro-1H-indazol-4(5H)-one's unique structural features make it a promising lead for the development of new pharmaceuticals, particularly in the areas where its specific interactions and properties can be harnessed to address various medical conditions.
Further research and development are necessary to fully understand the compound's pharmacological profile, safety, and efficacy before it can be utilized in clinical applications. 1-(2,3-Dimethylphenyl)-6,7-dihydro-1H-indazol-4(5H)-one's potential use in the pharmaceutical industry is based on its structural resemblance to known bioactive molecules and the possibility of it interacting with biological targets in a beneficial manner.
Check Digit Verification of cas no
The CAS Registry Mumber 1260653-09-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,6,0,6,5 and 3 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1260653-09:
(9*1)+(8*2)+(7*6)+(6*0)+(5*6)+(4*5)+(3*3)+(2*0)+(1*9)=135
135 % 10 = 5
So 1260653-09-5 is a valid CAS Registry Number.
1260653-09-5Relevant articles and documents
Optimization of Tetrahydroindazoles as Inhibitors of Human Dihydroorotate Dehydrogenase and Evaluation of Their Activity and in Vitro Metabolic Stability
Popova, Gergana,Ladds, Marcus J. G. W.,Johansson, Lars,Saleh, Aljona,Larsson, Johanna,Sandberg, Lars,Sahlberg, Sara H?ggblad,Qian, Weixing,Gullberg, Hjalmar,Garg, Neeraj,Gustavsson, Anna-Lena,Haraldsson, Martin,Lane, David,Yngve, Ulrika,Lain, Sonia
, p. 3915 - 3934 (2020/05/27)
Human dihydroorotate dehydrogenase (DHODH), an enzyme in the de novo pyrimidine synthesis pathway, is a target for the treatment of rheumatoid arthritis and multiple sclerosis and is re-emerging as an attractive target for cancer therapy. Here we describe the optimization of recently identified tetrahydroindazoles (HZ) as DHODH inhibitors. Several of the HZ analogues synthesized in this study are highly potent inhibitors of DHODH in an enzymatic assay, while also inhibiting cancer cell growth and viability and activating p53-dependent transcription factor activity in a reporter cell assay. Furthermore, we demonstrate the specificity of the compounds toward the de novo pyrimidine synthesis pathway through supplementation with an excess of uridine. We also show that induction of the DNA damage marker γ-H2AX after DHODH inhibition is preventable by cotreatment with the pan-caspase inhibitor Z-VAD-FMK. Additional solubility and in vitro metabolic stability profiling revealed compound 51 as a favorable candidate for preclinical efficacy studies.
